Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated. Although neoadjuvant-targeted therapy with EGFR-TKI and ALK-TKI showed good efficacy, there is no report of neoadjuvant-target...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2022-08-01
Sarja:	Frontiers in Oncology
Aiheet:	lung cancer BRAF V600E mutation neoadjuvant targeted therapy major pathologic response
Linkit:	https://www.frontiersin.org/articles/10.3389/fonc.2022.961539/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!